Bakkar Ashraf A, Wallerand Herve, Radvanyi François, Lahaye Jean-Baptiste, Pissard Serge, Lecerf Laure, Kouyoumdjian Jean Claude, Abbou Claude C, Pairon Jean-Claude, Jaurand Marie-Claude, Thiery Jean-Paul, Chopin Dominique K, de Medina Sixtina Gil Diez
Equipe mixte Inserm Institut National de la Santé et de la Recherche Médicale, and Service d'Urologie, Paris, France.
Cancer Res. 2003 Dec 1;63(23):8108-12.
FGFR3 and TP53 mutations are frequent in superficial papillary and invasive disease, respectively. We used denaturing high-performance liquid chromatography and sequencing to screen for FGFR3 and TP53 mutations in 81 newly diagnosed urothelial cell carcinomas. Tumors were classified as follows: 31 pTa, 1 carcinoma in situ, 30 pT1, and 19 pT2-T4. Tumor grades were as follows: 10 G1, 29 G2, and 42 G3. FGFR3 mutations were associated with low-stage (P < 0.0001), low-grade (P < 0.008) tumors, whereas TP53 mutations were associated with high-stage (P < 0.003), high-grade (P < 0.02) tumors. Mutations in these two genes were almost mutually exclusive. Our results suggest that FGFR3 and TP53 mutations define separate pathways at initial diagnosis of urothelial cell carcinoma.
FGFR3和TP53突变分别在浅表乳头状癌和浸润性疾病中较为常见。我们采用变性高效液相色谱法和测序技术，对81例新诊断的尿路上皮细胞癌进行FGFR3和TP53突变筛查。肿瘤分类如下：31例pTa期、1例原位癌、30例pT1期和19例pT2 - T4期。肿瘤分级如下：10例G1级、29例G2级和42例G3级。FGFR3突变与低分期（P < 0.0001）、低分级（P < 0.008）肿瘤相关，而TP53突变与高分期（P < 0.003）、高分级（P < 0.02）肿瘤相关。这两个基因的突变几乎相互排斥。我们的结果表明，在尿路上皮细胞癌初诊时，FGFR3和TP53突变定义了不同的途径。
Zotero 插件